Published in:
01-10-2005 | Article
Reduced insulin clearance contributes to the increased insulin levels after administration of glucagon-like peptide 1 in mice
Published in: Diabetologia | Issue 10/2005
Login to get accessAbstract
Aims/hypothesis
Glucagon-like peptide-1 (GLP-1) is known to be a potent stimulator of insulin secretion. However, whether GLP-1 also affects insulin clearance is not known. To explore this, we developed a technique to determine prehepatic insulin secretion in mice, based on deconvolution of plasma C-peptide concentrations. The estimated beta cell secretion was then related to plasma insulin levels to allow determination of clearance rate of endogenously produced insulin.
Materials and methods
Kinetic parameters of C-peptide were estimated after i.v. injection of human C-peptide (0.8 or 3 nmol/kg) or glucose (1 g/kg), either alone or together with GLP-1 (10 nmol/kg), in anaesthetised NMRI mice.
Results
C-peptide was distributed in two compartments (distribution volume 11.4±0.4 ml, 42±2% of which was in the accessible compartment). Fractional C-peptide clearance was 8.2±0.6% of the total distribution volume per minute. GLP-1 markedly enhanced prehepatic insulin secretion; more than 80% of prehepatic secretion occurred during the first minute after injection. Fractional clearance of endogenously released insulin after glucose was 0.66±0.11 min−1 and this was reduced to 0.36±0.10 min−1 by GLP-1 (p=0.04).
Conclusions/interpretation
It is possible to perform C-peptide deconvolution for estimating prehepatic insulin secretion in mice. GLP-1 reduces the clearance of endogenously released insulin; therefore, it may affect insulin levels by increasing prehepatic insulin secretion and by reducing insulin clearance.